AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
Read More
Tag: The Japanese Ministry of Health, Labour and Welfare
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
